All Stories

  1. Impact of concurrent antiplatelet use on the safety and efficacy of thromboprophylaxis with apixaban in patients with cancer: A post-hoc analysis of the AVERT trial

    Article • Thrombosis Research, May 2026, Elsevier

    Dr Alejandro Lazo-Langner

  2. Splanchnic vein thrombosis with and without myeloproliferative neoplasms: a comparative cohort study

    Article • Journal of Thrombosis and Haemostasis, May 2026, Elsevier

    Dr Alejandro Lazo-Langner

  3. Bleeding Risk with Apixaban vs. Rivaroxaban in Acute Venous Thromboembolism

    Article • The New England Journal of Medicine and Surgery and the Collateral Branches of Science, March 2026, New England Journal of Medicine (NEJM/MMS)

    Dr Alejandro Lazo-Langner

  4. Real-world thrombotic outcomes in patients with secondary erythrocytosis in comparison with polycythemia vera

    Article • Blood Red Cells & Iron, March 2026, Elsevier

    Dr Alejandro Lazo-Langner

  5. Patterns of presentation of suspected and confirmed recurrent venous thromboembolism in patients with prior venous thromboembolism

    Article • Research and Practice in Thrombosis and Haemostasis, March 2026, Elsevier

    Dr Alejandro Lazo-Langner

  6. Association Between Bariatric Surgery and the Long‐Term Risk for Venous Thromboembolism: A Population‐Based Matched Cohort Study

    Article • American Journal of Hematology, January 2026, Wiley

    Dr Alejandro Lazo-Langner

  7. Machine Learning for JAK2 Mutation Prediction in Erythrocytosis: Context Matters

    Article • Archives of Pathology & Laboratory Medicine, December 2025, Archives of Pathology and Laboratory Medicine

    Dr Alejandro Lazo-Langner

  8. Validation of the ToDay, a simplified diagnostic algorithm for deep vein thrombosis

    Article • Journal of Thrombosis and Haemostasis, December 2025, Elsevier

    Dr Alejandro Lazo-Langner

  9. Diagnosis, management, and outcomes of tumor-associated erythrocytosis: A systematic review

    Article • Blood, November 2025, American Society of Hematology

    Dr Alejandro Lazo-Langner

  10. Impact of concurrent antiplatelet/NSAID use on the safety and efficacy of thromboprophylaxis with apixaban in patients with cancer: A post-hoc analysis of the AVERT trial

    Article • Blood, November 2025, American Society of Hematology

    Dr Alejandro Lazo-Langner

  11. Racial disparities in the incidence and risk factors of major bleeding during extended anticoagulant therapy for venous thromboembolism

    Article • Journal of Thrombosis and Haemostasis, November 2025, Elsevier

    Dr Alejandro Lazo-Langner

  12. DOACs versus warfarin in AF with comorbid CKD or valvular disease: A systematic review and meta-analysis

    Article • Blood Vessels Thrombosis & Hemostasis, October 2025, Elsevier

    Dr Alejandro Lazo-Langner

  13. Diagnosis, management, and outcomes of drug-induced erythrocytosis: a systematic review

    Article • Blood Advances, April 2025, American Society of Hematology

    Dr Alejandro Lazo-Langner

  14. Daily Versus Non-Daily Oral Iron Supplementation for the Treatment of Iron Deficiency Anemia: A Systematic Review and Meta-Analysis of Randomized Trials

    Article • Blood, November 2024, American Society of Hematology

    Dr Alejandro Lazo-Langner

  15. Diagnosis, Management, and Outcomes of Drug-Induced Erythrocytosis: A Systematic Review

    Article • Blood, November 2024, American Society of Hematology

    Dr Alejandro Lazo-Langner

  16. Validation of a Simplified Diagnostic Algorithm for Deep Vein Thrombosis

    Article • Blood, November 2024, American Society of Hematology

    Dr Alejandro Lazo-Langner

  17. Are outcomes of locally advanced cervical cancer associated with prebrachytherapy hemoglobin values and transfusion practice? An observational study comparing two large academic centres with divergent clinical guidelines

    Article • Brachytherapy, November 2024, Elsevier

    Dr Alejandro Lazo-Langner

  18. Validation of a Simplified Diagnostic Algorithm for Deep Vein Thrombosis

    Article • Thrombosis Research, October 2024, Elsevier

    Dr Alejandro Lazo-Langner

  19. Physician practice patterns on the use of inferior vena cava filters in venous thromboembolism

    Article • Research and Practice in Thrombosis and Haemostasis, August 2024, Elsevier

    Dr Alejandro Lazo-Langner

  20. Serologic Response to Vaccine for COVID-19 in Patients with Hematologic Malignancy: A Prospective Cohort Study

    Article • Clinical Lymphoma Myeloma & Leukemia, May 2024, Elsevier

    Dr Alejandro Lazo-Langner

  21. Myelodysplastic Neoplasms (MDS) with Ring Sideroblasts or SF3B1 Mutations: The Improved Clinical Utility of World Health Organization and International Consensus Classification 2022 Definitions, a Single-Centre Retrospective Chart Review

    Article • Current Oncology, March 2024, MDPI AG

    Dr Alejandro Lazo-Langner

  22. Comparing DOACs with warfarin in AF patients with chronic kidney disease or valvular disease: A systematic review and meta-analysis

    Article • January 2024, Cold Spring Harbor Laboratory Press

    Dr Alejandro Lazo-Langner

  23. An Approach to the Investigation of Thrombocytosis: Differentiating between Essential Thrombocythemia and Secondary Thrombocytosis

    Article • Advances in Hematology, January 2024, Wiley

    Dr Alejandro Lazo-Langner

  24. Thrombosis and coagulopathy in COVID-19: A current narrative

    Article • January 2024, Elsevier

    Dr Alejandro Lazo-Langner

  25. Anticoagulant prophylaxis in pregnant women with a history of venous thromboembolism: A systematic review and meta-analysis

    Article • Thrombosis Update, December 2023, Elsevier

    Dr Alejandro Lazo-Langner

  26. Development of a Combined Risk Assessment Model for Venous Thromboembolism and Bleeding in Hematopoietic Stem Cell Transplantation Patients

    Article • Blood, November 2023, American Society of Hematology

    Dr Alejandro Lazo-Langner

  27. Risk of Bleeding and Thrombosis with CAR T-Cell Therapy: A Scoping Review

    Article • Blood, November 2023, American Society of Hematology

    Dr Alejandro Lazo-Langner

  28. SH2B3 Mutations in Patients with JAK2-Negative Erythrocytosis

    Article • Blood, November 2023, American Society of Hematology

    Dr Alejandro Lazo-Langner

  29. Venous Thromboembolism in Hematopoietic Stem Cell Transplantation

    Article • Blood, November 2023, American Society of Hematology

    Dr Alejandro Lazo-Langner

  30. Outpatient consolidation chemotherapy with intermediate dose cytarabine has similar survival and relapses rates in acute myeloid leukemia as compared to high dose cytarabine: A single center analysis

    Article • European Journal Of Haematology, August 2023, Wiley

    Dr Alejandro Lazo-Langner

  31. Acquired Hemophilia A Masquerading as Bleeding on Anticoagulation: A Case Report Including Key Laboratory Considerations

    Article • Cureus, June 2023, Springer Science + Business Media

    Dr Alejandro Lazo-Langner

  32. Risk of venous thromboembolism or hemorrhage among individuals with chronic kidney disease on prophylactic anticoagulant after hip or knee arthroplasty

    Article • American Journal of Hematology, June 2023, Wiley

    Dr Alejandro Lazo-Langner

  33. Venous thromboembolism in hematopoietic stem cell transplantation: A narrative review

    Article • Thrombosis Research, June 2023, Elsevier

    Dr Alejandro Lazo-Langner

  34. The risk of major bleeding in patients with factor V Leiden or prothrombin G20210A gene mutation while on extended anticoagulant treatment for venous thromboembolism

    Article • Journal of Thrombosis and Haemostasis, March 2023, Elsevier

    Dr Alejandro Lazo-Langner

  35. Anticoagulation strategies and outcomes during extracorporeal membrane oxygenation support: a single-centre pre-COVID-19 experience

    Article • Canadian Journal of Anesthesia/Journal canadien d anesthésie, January 2023, Springer Science + Business Media

    Dr Alejandro Lazo-Langner

  36. A Rational Approach to JAK2 Mutation Testing in Patients with Elevated Hemoglobin: Results from the JAK2 Prediction Cohort (JAKPOT) Study

    Article • Journal of General Internal Medicine, November 2022, Springer Science + Business Media

    Dr Alejandro Lazo-Langner

  37. A Prospective Study of Apixaban for Central Venous Catheter Associated Upper Extremity Deep Vein Thrombosis in Cancer Patients: Catheter 3

    Article • Blood, November 2022, American Society of Hematology

    Dr Alejandro Lazo-Langner

  38. Clinical Features and Mutational Landscape of Patients Referred for Suspected Essential Thrombocytosis: A Descriptive Study Using a 'Real-World’ Database

    Article • Blood, November 2022, American Society of Hematology

    Dr Alejandro Lazo-Langner

  39. The Impact of Artificial Intelligence on Health Equity in Oncology: Scoping Review

    Article • Journal of Medical Internet Research, November 2022, JMIR Publications Inc.

    Dr Alejandro Lazo-Langner

  40. Secondary causes of elevated hemoglobin in patients undergoing molecular testing for suspected polycythemia vera in southwestern Ontario: a chart review

    Article • CMAJ Open, October 2022, Canadian Medical Association (CMA)

    Dr Alejandro Lazo-Langner

  41. Which are the optimal thromboprophylaxis strategies for hospitalized patients with COVID-19? current controversies

    Article • Vascular, September 2022, SAGE Publications

    Dr Alejandro Lazo-Langner

  42. Predicting major bleeding during extended anticoagulation for unprovoked or weakly provoked venous thromboembolism

    Article • Blood Advances, August 2022, American Society of Hematology

    Dr Alejandro Lazo-Langner

  43. Venous and Arterial Thrombosis in Ambulatory and Discharged COVID-19 Patients: A Systematic Review and Meta-analysis

    Article • TH Open, July 2022, Thieme Publishing Group

    Dr Alejandro Lazo-Langner

  44. Clinical characteristics, multiorgan dysfunction and outcomes of patients with COVID-19: a prospective case series

    Article • CMAJ Open, July 2022, Canadian Medical Association (CMA)

    Dr Alejandro Lazo-Langner

  45. Thromboprophylaxis Strategies for Hospitalized Patients With COVID-19

    Article • CHEST Journal, July 2022, Elsevier

    Dr Alejandro Lazo-Langner

  46. Rivaroxaban for the treatment of noncirrhotic splanchnic vein thrombosis: an interventional prospective cohort study

    Article • Blood Advances, June 2022, American Society of Hematology

    Dr Alejandro Lazo-Langner

  47. COVID-19 vaccine humoral response and treatment effect in patients with hematologic malignancy.

    Article • Journal of Clinical Oncology, June 2022, American Society of Clinical Oncology (ASCO)

    Dr Alejandro Lazo-Langner

  48. P1019: A PREDICTION RULE TO GUIDE JAK2 MUTATION TESTING IN PATIENTS WITH SUSPECTED POLYCYTHEMIA VERA: RESULTS FROM THE JAK2 PREDICTION COHORT (JAKPOT) STUDY

    Article • HemaSphere, June 2022, Wiley

    Dr Alejandro Lazo-Langner

  49. Thrombolysis in the recovery of coagulated bone marrow aspirate samples

    Article • International Journal of Laboratory Hematology, May 2022, Wiley

    Dr Alejandro Lazo-Langner

  50. Association between genetic mutations and risk of venous thromboembolism in patients with solid tumor malignancies: A systematic review and meta-analysis

    Article • Thrombosis Research, May 2022, Elsevier

    Dr Alejandro Lazo-Langner

  51. Drug reaction with eosinophilia and systemic symptoms (DRESS): A tertiary care centre retrospective study

    Article • British Journal of Clinical Pharmacology, April 2022, Wiley

    Dr Alejandro Lazo-Langner

  52. The impact of red blood cell transfusion on mortality and treatment efficacy in patients treated with radiation: A systematic review

    Article • Clinical and Translational Radiation Oncology, March 2022, Elsevier

    Dr Alejandro Lazo-Langner

  53. Diagnosis of deep vein thrombosis with D-dimer adjusted to clinical probability: prospective diagnostic management study

    Article • BMJ, February 2022, BMJ

    Dr Alejandro Lazo-Langner

  54. Treatment of retinal vein thrombosis: what about anticoagulants?

    Article • Minerva Medica, February 2022, Edizioni Minerva Medica

    Dr Alejandro Lazo-Langner

  55. Serum erythropoietin levels in 696 patients investigated for erythrocytosis with JAK2 mutation analysis

    Article • American Journal of Hematology, January 2022, Wiley

    Dr Alejandro Lazo-Langner

  56. Risk for Recurrent Venous Thromboembolism in Patients With Subsegmental Pulmonary Embolism Managed Without Anticoagulation

    Article • Annals of Internal Medicine, January 2022, American College of Physicians

    Dr Alejandro Lazo-Langner

  57. Unexplained anemia of aging: Etiology, health consequences, and diagnostic criteria

    Article • Journal of the American Geriatrics Society, November 2021, Wiley

    Dr Alejandro Lazo-Langner

  58. A Prediction Rule to Guide JAK2 Testing in Patients with Suspected Polycythemia Vera

    Article • Blood, November 2021, American Society of Hematology

    Dr Alejandro Lazo-Langner

  59. Investigating Erythrocytosis: Changing Practice Patterns in the Era of Molecular Diagnostics

    Article • Blood, November 2021, American Society of Hematology

    Dr Alejandro Lazo-Langner

  60. Pragmatic Evaluation of an Algorithm Using D-Dimer Adjusted to Clinical Probability in the Diagnosis of Pulmonary Embolism

    Article • Blood, November 2021, American Society of Hematology

    Dr Alejandro Lazo-Langner

  61. Recurrent VTE in Pregnant Woman with Previous Personal History of VTE: A Systematic Review and Meta-Analysis

    Article • Blood, November 2021, American Society of Hematology

    Dr Alejandro Lazo-Langner

  62. Risk of Major Bleeding with Ibrutinib in Patients with Thrombocytopenia - a Retrospective Single-Center Canadian Study

    Article • Blood, November 2021, American Society of Hematology

    Dr Alejandro Lazo-Langner

  63. Rivaroxaban for Improvement in Thromboembolism Outcomes in Patients with Multiple Myeloma on Lenalidomide-Based Therapy: The Rithmm Feasibility Pilot Trial

    Article • Blood, November 2021, American Society of Hematology

    Dr Alejandro Lazo-Langner

  64. Spectrum of Myeloid Mutations in Patients with Elevated Hemoglobin

    Article • Blood, November 2021, American Society of Hematology

    Dr Alejandro Lazo-Langner

  65. The Impact of Artificial Intelligence on Health Equity in Oncology: A Scoping Review

    Article • Blood, November 2021, American Society of Hematology

    Dr Alejandro Lazo-Langner

  66. Treatment of Portal, Mesenteric, and Splenic Vein Thrombosis with Rivaroxaban: A Pilot, Prospective Cohort Study

    Article • Blood, November 2021, American Society of Hematology

    Dr Alejandro Lazo-Langner

  67. Reducing cytogenetic testing in the era of next generation sequencing: Are we choosing wisely?

    Article • International Journal of Laboratory Hematology, October 2021, Wiley

    Dr Alejandro Lazo-Langner

  68. Use of serology immunoassays for predicting SARS-CoV-2 infection: a serology-based diagnostic algorithm

    Article • October 2021, Cold Spring Harbor Laboratory Press

    Dr Alejandro Lazo-Langner

  69. MUFFIN-PTS trial, Micronized Purified Flavonoid Fraction for the Treatment of Post-Thrombotic Syndrome: protocol of a randomised controlled trial

    Article • BMJ Open, September 2021, BMJ

    Dr Alejandro Lazo-Langner

  70. APTT therapeutic range for monitoring unfractionated heparin therapy. Significant impact of the anti‐Xa reagent used for correlation: COMMENT

    Article • Journal of Thrombosis and Haemostasis, August 2021, Elsevier

    Dr Alejandro Lazo-Langner

  71. Venous Thromboembolism in Hospitalized Critical and Noncritical COVID-19 Patients: A Systematic Review and Meta-analysis

    Article • TH Open, July 2021, Thieme Publishing Group

    Dr Alejandro Lazo-Langner

  72. COVID-19 vaccine-induced immune thrombotic thrombocytopenia: An emerging cause of splanchnic vein thrombosis

    Article • Annals of Hepatology, July 2021, Elsevier

    Dr Alejandro Lazo-Langner

  73. Postoperative low molecular weight heparin bridging treatment for patients at high risk of arterial thromboembolism (PERIOP2): double blind randomised controlled trial

    Article • BMJ, June 2021, BMJ

    Dr Alejandro Lazo-Langner

  74. Splanchnic vein thrombosis: Clinical manifestations, risk factors, management, and outcomes

    Article • Thrombosis Research, June 2021, Elsevier

    Dr Alejandro Lazo-Langner

  75. A case of congenital prothrombin deficiency with two concurrent mutations in the prothrombin gene

    Article • Research and Practice in Thrombosis and Haemostasis, May 2021, Elsevier

    Dr Alejandro Lazo-Langner

  76. Paediatric serum sickness-like reaction: A 10-year retrospective cohort study

    Article • Paediatrics & Child Health, April 2021, Oxford University Press (OUP)

    Dr Alejandro Lazo-Langner

  77. Current estimates of the incidence of acute venous thromboembolic disease in Canada: A meta-analysis

    Article • Thrombosis Research, January 2021, Elsevier

    Dr Alejandro Lazo-Langner

  78. Development and implementation of common data elements for venous thromboembolism research: on behalf of SSC Subcommittee on official Communication from the SSC of the ISTH

    Article • Journal of Thrombosis and Haemostasis, January 2021, Elsevier

    Dr Alejandro Lazo-Langner

  79. Association between Genetic Mutations and Risk of Venous Thromboembolism in Patients with Solid Tumor Malignancies: A Systematic Review and Meta-Analysis

    Article • Blood, November 2020, American Society of Hematology

    Dr Alejandro Lazo-Langner

  80. Deep Vein Thrombosis Diagnosis with D-Dimer Adjusted to Clinical Probability

    Article • Blood, November 2020, American Society of Hematology

    Dr Alejandro Lazo-Langner

  81. Identifying Myeloid Mutations By NGS in Patients with Unexplained Erythrocytosis

    Article • Blood, November 2020, American Society of Hematology

    Dr Alejandro Lazo-Langner

  82. Prevalence of Thrombophilia in Transient Ischemic Attack and Ischemic Stroke Patients

    Article • Blood, November 2020, American Society of Hematology

    Dr Alejandro Lazo-Langner

  83. Reducing Cytogenetic Testing in the Era of Next Generation Sequencing (NGS); Are We Choosing Wisely?

    Article • Blood, November 2020, American Society of Hematology

    Dr Alejandro Lazo-Langner

  84. Establishing diagnostic criteria and treatment of subsegmental pulmonary embolism: A Delphi analysis of experts

    Article • Research and Practice in Thrombosis and Haemostasis, November 2020, Elsevier

    Dr Alejandro Lazo-Langner, Luis Jara-Palomares

  85. Thrombophilia testing in patients receiving rivaroxaban or apixaban for the treatment of venous thromboembolism

    Article • Thrombosis Research, November 2020, Elsevier

    Dr Alejandro Lazo-Langner

  86. Long term monitoring of patients with positive lupus anticoagulant and antiphospholipid antibodies. Are all cases persistently positive?

    Article • Thrombosis Research, October 2020, Elsevier

    Dr Alejandro Lazo-Langner

  87. Thrombosis risk associated with COVID-19 infection. A scoping review

    Article • Thrombosis Research, August 2020, Elsevier

    Dr Alejandro Lazo-Langner

  88. Bleeding Risk in Nonvalvular Atrial Fibrillation Patients Receiving Direct Oral Anticoagulants and Warfarin: A Systematic Review and Meta-Analysis of Observational Studies

    Article • TH Open, July 2020, Thieme Publishing Group

    Dr Alejandro Lazo-Langner

  89. Anabolic steroids in myelodysplastic syndromes: A systematic review

    Article • Leukemia Research, July 2020, Elsevier

    Dr Alejandro Lazo-Langner

  90. Clinical value of next‐generation sequencing compared to cytogenetics in patients with suspected myelodysplastic syndrome

    Article • British Journal of Haematology, June 2020, Wiley

    Dr Alejandro Lazo-Langner

  91. Development of a Clinical Prediction Rule for Venous Thromboembolism in Patients with Acute Leukemia

    Article • Thrombosis and Haemostasis, January 2020, Thieme Publishing Group

    Dr Alejandro Lazo-Langner

  92. Efficacy and safety of four-factor prothrombin complex concentrate fixed, weight-based dosing for reversal of warfarin anticoagulation

    Article • Hematology, January 2020, Taylor & Francis

    Dr Alejandro Lazo-Langner

  93. Diagnosis of Pulmonary Embolism with d -Dimer Adjusted to Clinical Probability

    Article • The New England Journal of Medicine and Surgery and the Collateral Branches of Science, November 2019, New England Journal of Medicine (NEJM/MMS)

    Dr Alejandro Lazo-Langner

  94. Serum Sickness-Like Reaction in Children: Review of the Literature

    Article • EMJ Dermatology, November 2019, European Medical Group

    Dr Alejandro Lazo-Langner

  95. Anabolic Steroids in Myelodysplastic Syndromes: A Systematic Review

    Article • Blood, November 2019, American Society of Hematology

    Dr Alejandro Lazo-Langner

  96. Bleeding Risk in Non-Valvular Atrial Fibrillation Patients Receiving Direct Oral Anticoagulants and Warfarin: A Systematic Review and Meta-Analysis of Observational Studies

    Article • Blood, November 2019, American Society of Hematology

    Dr Alejandro Lazo-Langner

  97. Efficacy and Safety of Direct Oral Anticoagulants in Obese Patients with Venous Thromboembolism

    Article • Blood, November 2019, American Society of Hematology

    Dr Alejandro Lazo-Langner

  98. Reevaluating the Role of Cytogenetic Testing in Patients with Suspected Myelodysplastic Syndrome in the Era of Next Generation Sequencing

    Article • Blood, November 2019, American Society of Hematology

    Dr Alejandro Lazo-Langner

  99. The Impact of Red Blood Cell Transfusion on Mortality and Treatment Efficacy in Patients Treated with Radiation: A Systematic Review of the Literature

    Article • Blood, November 2019, American Society of Hematology

    Dr Alejandro Lazo-Langner

  100. Implementation of an NGS‐based sequencing and gene fusion panel for clinical screening of patients with suspected hematologic malignancies

    Article • European Journal Of Haematology, July 2019, Wiley

    Dr Alejandro Lazo-Langner

  101. Studies in upper extremity deep vein thrombosis: Addressing the knowledge gaps

    Article • Research and Practice in Thrombosis and Haemostasis, July 2019, Elsevier

    Dr Alejandro Lazo-Langner

  102. Management of Cancer-Associated Anemia With Erythropoiesis-Stimulating Agents: ASCO/ASH Clinical Practice Guideline Update

    Article • Journal of Oncology Practice, July 2019, American Society of Clinical Oncology (ASCO)

    Dr Alejandro Lazo-Langner

  103. Treatment of venous thromboembolism in acute leukemia: A systematic review

    Article • Thrombosis Research, June 2019, Elsevier

    Dr Alejandro Lazo-Langner

  104. S1642 DEVELOPMENT OF A CLINICAL PREDICTION RULE FOR VENOUS THROMBOEMBOLISM IN PATIENTS WITH ACUTE LEUKEMIA

    Article • HemaSphere, June 2019, Wiley

    Dr Alejandro Lazo-Langner

  105. Management of Cancer-Associated Anemia With Erythropoiesis-Stimulating Agents: ASCO/ASH Clinical Practice Guideline Update

    Article • Journal of Clinical Oncology, May 2019, American Society of Clinical Oncology (ASCO)

    Dr Alejandro Lazo-Langner

  106. Management of cancer-associated anemia with erythropoiesis-stimulating agents: ASCO/ASH clinical practice guideline update

    Article • Blood Advances, April 2019, American Society of Hematology

    Dr Alejandro Lazo-Langner, Dr Massimo Martino

  107. Long term follow-up after liver transplantation from a JAK2 mutation positive donor

    Article • HepatoBiliary Surgery and Nutrition, April 2019, AME Publishing Company

    Vivian Charles McAlister, Dr Alejandro Lazo-Langner

  108. Apixaban to Prevent Venous Thromboembolism in Patients with Cancer

    Article • The New England Journal of Medicine and Surgery and the Collateral Branches of Science, February 2019, New England Journal of Medicine (NEJM/MMS)

    Dr Alejandro Lazo-Langner

  109. A Case of SF3B1-Positive Myelodysplastic/Myeloproliferative Neoplasm with Ring Sideroblasts and Thrombocytosis

    Article • Turkish Journal of Hematology, February 2019, Journal of Clinical Research of Pediatric Endocrinology

    Dr Alejandro Lazo-Langner

  110. Post-thrombotic syndrome and recurrent thromboembolism in patients with upper extremity deep vein thrombosis: A systematic review and meta-analysis

    Article • Thrombosis Research, February 2019, Elsevier

    Dr Alejandro Lazo-Langner

  111. Large expert-curated database for benchmarking document

    Article • Database, January 2019, Oxford University Press (OUP)

    Dr Daniel Prieto, Associate Professor James A.L. Brown, Professor Amanda G Thrift, Docent Kutty Selva Nandakumar, Professor Miguel Viveiros, MD Diego A. Valera-Cornejo, Dr Soroush Safaei, Dr Carmen San Martín, Piero Carninci, Dr Florian Rehfeldt, Dr Yoichi Watanabe, Kazuki Ide, Mr Alvin Wong, PD Dr. Adrian Meule, Dr Maurizio Petrelli, Dr Christine McGarrigle, Dr Tristan Reddan, Dr Nicola Roberts, Professor Stefan Lorkowski, Dr Cyrille Goarant, Dr Emma C Hobbs, Dr. Saurab Sharma, Ph.D., Dr Farid Rahimi, Prof. Iseult Lynch, Mirella Walker, Dr Luca Galluzzi, Sophie Ohlsson, Professor Tullio Florio, Dr Rabea A Gadelkareem, Dr Azubuike Christian Ukubuiwe, Prof Gajendra PS Raghava, Prof Jun Shen, Lubna Razak, ABHISHEKA BANSAL, Craig Billington, Dr Alejandro Lazo-Langner, Joan Albiol, MOURAD TAYEBI, Chuang Ma, Christine Toelzer , Dr. Kathrin Karsay, Professor Andrew M Beale, Professor Hugh James Byrne, Dr Ugo Marzocchi, Ana Nordberg, Martin Bartas, Natalia Echeverría, Dr Patricia M Graves, Dr Elvis A F Martis, Dr marco cascella, Dr. Giuseppe Lanza, Dr Michael Boah, Professor Bryan M. Wong, Luria Founou

  112. Distribution of lymphomas in Mexico: a multicenter descriptive study

    Article • Journal of Hematopathology, December 2018, Springer Science + Business Media

    Dr Alejandro Lazo-Langner

  113. Development of a Clinical Prediction Rule for the Risk of Venous Thromboembolism in Patients with Acute Leukemia

    Article • Blood, November 2018, American Society of Hematology

    Dr Alejandro Lazo-Langner

  114. Double Blind Randomized Control Trial of Postoperative Low Molecular Weight Heparin Bridging Therapy for Patients Who Are at High Risk for Arterial Thromboembolism (PERIOP 2)

    Article • Blood, November 2018, American Society of Hematology

    Dr Alejandro Lazo-Langner

  115. Quantitative Modeling of Ineffective Hematopoiesis in Myelodysplastic Syndrome Patients Yields Distinct Clinical Phenotypes and Can Identify a State of Disease Predictive of Loss of Response to Azacitidine

    Article • Blood, November 2018, American Society of Hematology

    Dr Alejandro Lazo-Langner

  116. Safe Start of Ibrutinib in Patients with Chronic Lymphocytic Leukemia and Uncontrolled Autoimmune Hemolytic Anemia

    Article • Blood, November 2018, American Society of Hematology

    Dr Alejandro Lazo-Langner

  117. A case of SF3B1 positive myelodysplastic/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis

    Article • Turkish Journal of Hematology, November 2018, Journal of Clinical Research of Pediatric Endocrinology

    Dr Alejandro Lazo-Langner

  118. Erratum to: Prothrombin Complex Concentrate for Major Bleeding on Factor Xa Inhibitors: A Prospective Cohort Study

    Article • Thrombosis and Haemostasis, November 2018, Thieme Publishing Group

    Dr Alejandro Lazo-Langner

  119. A matched case-control study to assess the association between non-steroidal anti-inflammatory drug use and thrombotic microangiopathy

    Article • PLOS One, August 2018, PLOS

    Dr Alejandro Lazo-Langner

  120. Immigration, region of origin, and the epidemiology of venous thromboembolism: A population‐based study

    Article • Research and Practice in Thrombosis and Haemostasis, July 2018, Elsevier

    Dr Alejandro Lazo-Langner

  121. Prevention of venous thromboembolism in pregnant patients with a history of venous thromboembolic disease: A retrospective cohort study

    Article • Thrombosis Research, July 2018, Elsevier

    Dr Alejandro Lazo-Langner

  122. Standardization of extracellular vesicle measurements by flow cytometry through vesicle diameter approximation

    Article • Journal of Thrombosis and Haemostasis, June 2018, Elsevier

    Dr Alejandro Lazo-Langner

  123. Adherence to, and Outcomes of, a Galactomannan Screening Protocol in High-Risk Hematology Patients

    Article • Current Oncology, April 2018, MDPI AG

    Dr Alejandro Lazo-Langner

  124. Prothrombin Complex Concentrate for Major Bleeding on Factor Xa Inhibitors: A Prospective Cohort Study

    Article • Thrombosis and Haemostasis, March 2018, Thieme Publishing Group

    Dr Alejandro Lazo-Langner

  125. A prospective study of Rivaroxaban for central venous catheter associated upper extremity deep vein thrombosis in cancer patients (Catheter 2)

    Article • Thrombosis Research, February 2018, Elsevier

    Dr Alejandro Lazo-Langner

  126. Systematic review of azacitidine regimens in myelodysplastic syndrome and acute myeloid leukemia

    Article • BMC Hematology, January 2018, Springer Science + Business Media

    Dr Alejandro Lazo-Langner

  127. Risk of Venous Thromboembolism in Patients by Albuminuria and Estimated GFR

    Article • American Journal of Kidney Diseases, December 2017, Elsevier

    Dr Alejandro Lazo-Langner

  128. Health-related quality of life in children with cutaneous adverse drug reactions

    Article • Pediatric Dermatology, September 2017, Wiley

    Dr Alejandro Lazo-Langner

  129. Erythropoiesis-stimulating agents in elderly patients with anemia: response and cardiovascular outcomes

    Article • Blood Advances, August 2017, American Society of Hematology

    Dr Alejandro Lazo-Langner

  130. Cost effectiveness of the addition of a comprehensive CT scan to the abdomen and pelvis for the detection of cancer after unprovoked venous thromboembolism

    Article • Thrombosis Research, March 2017, Elsevier

    Dr Alejandro Lazo-Langner

  131. Blood donation and testosterone replacement therapy

    Article • Transfusion, February 2017, Wiley

    Dr Alejandro Lazo-Langner

  132. Impact of thrombophilia screening on venous thromboembolism management practices

    Article • Thrombosis Research, January 2017, Elsevier

    Dr Alejandro Lazo-Langner

  133. A Pilot Study in Cancer Patients with Central Venous Catheter Associated Deep Vein Thrombosis in Upper Extremity Treated with Rivaroxaban (Catheter 2)

    Article • Blood, December 2016, American Society of Hematology

    Dr Alejandro Lazo-Langner

  134. Blood Donation May Not Reduce Risk of Testosterone-Induced Polycythemia

    Article • Blood, December 2016, American Society of Hematology

    Dr Alejandro Lazo-Langner

  135. Comparison of the IPSS and IPSS-R in Predicting Survival and Response of Myelodysplastic Syndrome Patients to 5-Azacitidine

    Article • Blood, December 2016, American Society of Hematology

    Dr Alejandro Lazo-Langner

  136. Efficacy and Safety of Direct Oral Anticoagulants: A Systematic Review of Population Based Studies

    Article • Blood, December 2016, American Society of Hematology

    Dr Alejandro Lazo-Langner

  137. Erythropoiesis-Stimulating Agents in Elderly Patients with Anemia of Unknown Etiology: Treatment Response and Cardiovascular Outcomes

    Article • Blood, December 2016, American Society of Hematology

    Dr Alejandro Lazo-Langner

  138. Long Term Monitoring of Patients with Positive Lupus Anticoagulant and Antiphospholipid Antibodies. Are All Cases Persistently Positive?

    Article • Blood, December 2016, American Society of Hematology

    Dr Alejandro Lazo-Langner

  139. Lupus Anticoagulant Testing in Patients Receiving Rivaroxaban or Apixaban for the Treatment of Venous Thromboembolism

    Article • Blood, December 2016, American Society of Hematology

    Dr Alejandro Lazo-Langner

  140. Post-Thrombotic Syndrome and Functional Disability in Patients with Upper Extremity Deep Vein Thrombosis: A Prospective Cohort Study

    Article • Blood, December 2016, American Society of Hematology

    Dr Alejandro Lazo-Langner

  141. Safety of Weight-Adjusted Dosing of LMWH in Clinically Obese Cancer Patients with Venous Thromboembolism

    Article • Blood, December 2016, American Society of Hematology

    Dr Alejandro Lazo-Langner

  142. Retinal vein thrombosis: The Internist's role in the etiologic and therapeutic management

    Article • Thrombosis Research, December 2016, Elsevier

    Dr Alejandro Lazo-Langner

  143. Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis in Children: A Literature Review of Current Treatments

    Article • EMJ Dermatology, November 2016, European Medical Group

    Dr Alejandro Lazo-Langner

  144. eculizumab in PNH

    Article • Therapeutics and Clinical Risk Management, August 2016, Dove Medical Press

    Dr. Fatimah FA Al-Ani, Dr Alejandro Lazo-Langner

  145. A multicenter prospective study of risk factors and treatment of unusual site thrombosis

    Article • Thrombosis Research, August 2016, Elsevier

    Dr Alejandro Lazo-Langner

  146. Erythropoietin Levels in Elderly Patients with Anemia of Unknown Etiology

    Article • PLOS One, June 2016, PLOS

    Dr Alejandro Lazo-Langner

  147. Effect of unintentional cyclophosphamide underdosing on diffuse large B-cell lymphoma response to chemotherapy: a retrospective review

    Article • CMAJ Open, May 2016, Canadian Medical Association (CMA)

    Dr Alejandro Lazo-Langner

  148. Risk factors predictive of occult cancer detection in patients with unprovoked venous thromboembolism

    Article • Blood, April 2016, American Society of Hematology

    Dr Alejandro Lazo-Langner

  149. Randomized double-blind safety comparison of intravenous iron dextran versus iron sucrose in an adult non-hemodialysis outpatient population: A feasibility study

    Article • BMC Hematology, March 2016, Springer Science + Business Media

    Dr Alejandro Lazo-Langner

  150. Erythropoietin in anemia of unknown etiology: A systematic review and meta-analysis

    Article • Hematology, January 2016, Taylor & Francis

    Dr Alejandro Lazo-Langner

  151. Guidance for the management of venous thrombosis in unusual sites

    Article • Journal of Thrombosis and Thrombolysis, January 2016, Springer Science + Business Media

    Dr Alejandro Lazo-Langner

  152. The effect of low-dose oral vitamin K supplementation on INR stability in patients receiving warfarin

    Article • Thrombosis and Haemostasis, January 2016, Thieme Publishing Group

    Dr Alejandro Lazo-Langner

  153. A Prospective Cohort Study of Upper Extremity Deep Vein Thrombosis

    Article • Blood, December 2015, American Society of Hematology

    Dr Alejandro Lazo-Langner

  154. Dabigatran Pharmacokinetics and Pharmacodynamics during Renal Replacement Therapy

    Article • Blood, December 2015, American Society of Hematology

    Dr Alejandro Lazo-Langner

  155. Erythropoietin in Elderly Patients with Anemia of Unknown Etiology

    Article • Blood, December 2015, American Society of Hematology

    Dr Alejandro Lazo-Langner

  156. Evaluating the Effect of Ethnicity on the Risk of Venous Thromboembolism (VTE): A Systematic Review

    Article • Blood, December 2015, American Society of Hematology

    Dr Alejandro Lazo-Langner

  157. Evaluating the Need for Anticoagulation Beyond 6 Months for Patients with Cancer-Associated Venous Thromboembolism (VTE): A Retrospect of Real Life (EXTEND study - updated results)

    Article • Blood, December 2015, American Society of Hematology

    Dr Alejandro Lazo-Langner

  158. Management of T-Cell Large Granular Lymphocyte Leukemia with Methotrexate or Cyclophosphamide

    Article • Blood, December 2015, American Society of Hematology

    Dr Alejandro Lazo-Langner

  159. Risk Factors Predictive of Occult Cancer Detection in Patients with Unprovoked Venous Thromboembolism

    Article • Blood, December 2015, American Society of Hematology

    Dr Alejandro Lazo-Langner

  160. Systematic Review of the Efficacy and Safety of Alternative Azacitidine Regimens in Myelodysplastic Syndrome

    Article • Blood, December 2015, American Society of Hematology

    Dr Alejandro Lazo-Langner

  161. Updates on the Risk of Dalteparin Thromboprophylaxis Failure in Hospitalized Acutely Ill Medical Patients with Cancer (ARTIC STUDY)

    Article • Blood, December 2015, American Society of Hematology

    Dr Alejandro Lazo-Langner

  162. Validation of Predictive Models for Response to Erythropoiesis-Stimulating Agents in Myelodysplastic Syndromes

    Article • Blood, December 2015, American Society of Hematology

    Dr Alejandro Lazo-Langner

  163. Identifying venous thromboembolism and major bleeding in emergency room discharges using administrative data

    Article • Thrombosis Research, December 2015, Elsevier

    Dr Alejandro Lazo-Langner

  164. Screening for Occult Cancer in Unprovoked Venous Thromboembolism

    Article • Journal of Vascular Surgery, December 2015, Elsevier

    Dr Alejandro Lazo-Langner

  165. Association between inflammation biomarkers, anatomic extent of deep venous thrombosis, and venous symptoms after deep venous thrombosis

    Article • Journal of Vascular Surgery Venous and Lymphatic Disorders, October 2015, Elsevier

    Dr Alejandro Lazo-Langner

  166. Review: In AF or VTE, direct oral anticoagulants reduce fatal bleeding compared with vitamin K antagonists

    Article • Annals of Internal Medicine, October 2015, American College of Physicians

    Dr Alejandro Lazo-Langner

  167. Screening for Occult Cancer in Unprovoked Venous Thromboembolism

    Article • The New England Journal of Medicine and Surgery and the Collateral Branches of Science, August 2015, New England Journal of Medicine (NEJM/MMS)

    Dr Alejandro Lazo-Langner

  168. Quality of life in children with adverse drug reactions: a narrative and systematic review

    Article • British Journal of Clinical Pharmacology, July 2015, Wiley

    Dr Alejandro Lazo-Langner

  169. Screening of Patients with Idiopathic Venous Thromboembolism for Paroxysmal Nocturnal Hemoglobinuria Clones

    Article • Thrombosis Research, June 2015, Elsevier

    Dr Alejandro Lazo-Langner

  170. Inflammation markers and their trajectories after deep vein thrombosis in relation to risk of post-thrombotic syndrome

    Article • Journal of Thrombosis and Haemostasis, February 2015, Wiley

    Dr Alejandro Lazo-Langner

  171. Fondaparinux for the treatment of suspected heparin-induced thrombocytopenia: a propensity score–matched study

    Article • Blood, February 2015, American Society of Hematology

    Dr Alejandro Lazo-Langner

  172. Clinical Challenges in Patients with Cancer-Associated Thrombosis: Canadian Expert Consensus Recommendations

    Article • Current Oncology, February 2015, MDPI AG

    Dr Alejandro Lazo-Langner

  173. Assessment of Risk of Thromboprophylaxis Failure in Hospitalized Patients with Cancer (Artic Study)

    Article • Blood, December 2014, American Society of Hematology

    Dr Alejandro Lazo-Langner

  174. Detection of Paroxysmal Nocturnal Hemoglobinuria Clones in Patients with Idiopathic Venous Thromboembolism

    Article • Blood, December 2014, American Society of Hematology

    Dr Alejandro Lazo-Langner

  175. Effect of Unintentional Cyclophosphamide Under-Dosing on Disease Response and Outcomes in Patients with Diffuse Large B-Cell Lymphoma

    Article • Blood, December 2014, American Society of Hematology

    Dr Alejandro Lazo-Langner

  176. Efficacy and safety of Prothrombin Complex Concentrates Weight-Based Dosing for Reversal of Warfarin Anticoagulation

    Article • Blood, December 2014, American Society of Hematology

    Dr Alejandro Lazo-Langner

  177. Evaluating the Need for Anticoagulation Beyond 6 Months for Patients with Cancer-Associated Venous Thromboembolism: A Retrospect of Real Life (EXTEND Study)

    Article • Blood, December 2014, American Society of Hematology

    Dr Alejandro Lazo-Langner

  178. Impact of Transition to Generic Imatinib in the Molecular Response Among Patients with Chronic Myeloid Leukemia

    Article • Blood, December 2014, American Society of Hematology

    Dr Alejandro Lazo-Langner

  179. Coagulation problems in the critically ill

    Article • December 2014, Cambridge University Press

    Dr Alejandro Lazo-Langner

  180. Response to “Need to Minimize Bias When Surveying Patient Attitudes to Stopping cml Treatment”

    Article • Current Oncology, December 2014, MDPI AG

    Dr Alejandro Lazo-Langner

  181. Rivaroxaban vs. low molecular weight heparin for the prevention of venous thromboembolism after hip or knee arthroplasty: a cohort study

    Article • Journal of Thrombosis and Haemostasis, October 2014, Elsevier

    Dr Alejandro Lazo-Langner

  182. The effect of low molecular weight heparin on survival in cancer patients: an updated systematic review and meta‐analysis of randomized trials: reply

    Article • Journal of Thrombosis and Haemostasis, September 2014, Elsevier

    Dr Alejandro Lazo-Langner

  183. Genetic polymorphisms of vein wall remodeling in chronic venous disease: a narrative and systematic review

    Article • Blood, August 2014, American Society of Hematology

    Dr Alejandro Lazo-Langner

  184. The effect of low molecular weight heparin on survival in cancer patients: an updated systematic review and meta‐analysis of randomized trials

    Article • Journal of Thrombosis and Haemostasis, July 2014, Elsevier

    Dr Alejandro Lazo-Langner

  185. Patient preferences for stopping tyrosine kinase inhibitors in chronic myeloid leukemia

    Article • Current Oncology, April 2014, MDPI AG

    Dr Alejandro Lazo-Langner

  186. Acute myeloid leukemia relapse first presenting in the cerebrospinal fluid

    Article • Blood, January 2014, American Society of Hematology

    Dr Alejandro Lazo-Langner

  187. Initial Management of Noncirrhotic Splanchnic Vein Thrombosis: When Is Anticoagulation Enough?

    Article • Canadian Journal of Gastroenterology and Hepatology, January 2014, Hindawi Publishing Corporation

    Dr Alejandro Lazo-Langner

  188. A Systematic Review Of The Role Of Erythropoietin In The Pathophysiology Of Anemia In Elderly Patients

    Article • Blood, November 2013, American Society of Hematology

    Dr Alejandro Lazo-Langner

  189. Inflammation Markers and The Risk Of Post Thrombotic Syndrome: Results From The Bio-Sox Study

    Article • Blood, November 2013, American Society of Hematology

    Dr Alejandro Lazo-Langner

  190. Rivaroxaban Versus Low Molecular Weight Heparin For The Prevention Of Venous Thromboembolism After Orthopedic Surgery: A Population-Based Study

    Article • Blood, November 2013, American Society of Hematology

    Dr Alejandro Lazo-Langner

  191. Effect of anticoagulants and antiplatelet agents on the efficacy of intravesical BCG treatment of bladder cancer: A systematic review

    Article • Canadian Urological Association Journal, November 2013, Canadian Urological Association Journal

    Dr Alejandro Lazo-Langner

  192. Clinical performance of bleeding risk scores for predicting major and clinically relevant non‐major bleeding events in patients receiving warfarin

    Article • Journal of Thrombosis and Haemostasis, September 2013, Elsevier

    Dr Alejandro Lazo-Langner

  193. The equipoise of perioperative anticoagulation management: a Canadian cross-sectional survey

    Article • Journal of Thrombosis and Thrombolysis, July 2013, Springer Science + Business Media

    Dr Alejandro Lazo-Langner

  194. Predictors of unsuccessful mobilization with granulocyte colony‐stimulating factor alone in patients undergoing autologous hematopoietic stem cell transplantation

    Article • Journal of Clinical Apheresis, February 2013, Wiley

    Dr Alejandro Lazo-Langner

  195. Cisplatin and Short-Term 5-Fluorouracil Infusion for Paraneoplastic Microangiopathic Hemolytic Anemia in Gastric Cancer: A Case Report and Review of the Literature

    Article • Case Reports in Oncological Medicine, January 2013, Hindawi Publishing Corporation

    Dr Alejandro Lazo-Langner

  196. Kidney and Pancreatic Extramedullary Relapse in Adult Acute Lymphoblastic Leukemia: A Case Report and Review of the Literature

    Article • Case Reports in Hematology, January 2013, Wiley

    Dr Alejandro Lazo-Langner

  197. Spontaneous Retroperitoneal Hemorrhage in a Patient with Prolymphocytic Transformation of Chronic Lymphocytic Leukemia

    Article • Case Reports in Hematology, January 2013, Wiley

    Dr Alejandro Lazo-Langner

  198. Cardiac Conduction Block at Multiple Levels Caused by Arsenic Trioxide Therapy

    Article • Canadian Journal of Cardiology, January 2013, Elsevier

    Dr Alejandro Lazo-Langner

  199. Clinical review: Clinical management of new oral anticoagulants: a structured review with emphasis on the reversal of bleeding complications

    Article • Critical Care, January 2013, Springer Science + Business Media

    Dr Alejandro Lazo-Langner

  200. Myelodyspastic syndrome with complex cytogenetics

    Article • Blood, November 2012, American Society of Hematology

    Dr Alejandro Lazo-Langner

  201. Determining the Correlation Between Antiphospholipid Antibodies and Epilepsy: A Systematic Review

    Article • Blood, November 2012, American Society of Hematology

    Dr Alejandro Lazo-Langner

  202. Fondaparinux Versus Argatroban and Danaparoid for the Treatment of Suspected or Confirmed Heparin-Induced Thrombocytopenia: A Propensity Score Analysis.

    Article • Blood, November 2012, American Society of Hematology

    Dr Alejandro Lazo-Langner

  203. Impact of Thrombophilia Screening On Venous Thromboembolism Management Practices

    Article • Blood, November 2012, American Society of Hematology

    Dr Alejandro Lazo-Langner

  204. Non-Cirrhotic Splanchnic Vein Thrombosis: When Is Anticoagulation Enough?

    Article • Blood, November 2012, American Society of Hematology

    Dr Alejandro Lazo-Langner

  205. Patient Preferences for Stopping Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia

    Article • Blood, November 2012, American Society of Hematology

    Dr Alejandro Lazo-Langner

  206. New oral anticoagulants

    Article • Canadian Medical Association Journal, November 2012, Canadian Medical Association (CMA)

    Dr Alejandro Lazo-Langner

  207. Conservative perioperative anticoagulation management in patients with chronic venous thromboembolic disease: a cohort study

    Article • Journal of Thrombosis and Haemostasis, November 2012, Elsevier

    Dr Alejandro Lazo-Langner

  208. Common Dermatoses in Children Referred to a Specialized Pediatric Dermatology Service in Mexico: A Comparative Study between Two Decades

    Article • ISRN Dermatology, October 2012, Hindawi Publishing Corporation

    Dr Alejandro Lazo-Langner

  209. Histoplasmosis-induced pancytopenia

    Article • Blood, October 2012, American Society of Hematology

    Dr Alejandro Lazo-Langner

  210. Canadian Surgery Forum1 Is laparoscopic sleeve gastrectomy a reasonable stand-alone procedure for super morbidly obese patients?2 Postoperative monitoring requirements of patients with obstructive sleep apnea undergoing bariatric surgery3 Role of relap...

    Article • Canadian Journal of Surgery, August 2012, Canadian Medical Association (CMA)

    Dr Alejandro Lazo-Langner

  211. Development of a Clinical Prediction Rule for Risk Stratification of Recurrent Venous Thromboembolism in Patients With Cancer-Associated Venous Thromboembolism

    Article • Circulation, July 2012, Wolters Kluwer Health

    Dr Alejandro Lazo-Langner

  212. Acute myeloid leukemia with promyelocytic morphology lacking RARA rearrangement and with double minutes, MYC deletion and 2 cell lines with amplification of MYC region: case report and literature review

    Article • Journal of Hematopathology, July 2012, Springer Science + Business Media

    Dr Alejandro Lazo-Langner

  213. Correlation between Antiphospholipid Antibodies and Epilepsy: A Systematic Review (P02.154)

    Article • Neurology, April 2012, Wolters Kluwer Health

    Dr Alejandro Lazo-Langner

  214. Acute nonlymphocytic leukemia presenting with pancytopenia

    Article • Blood, February 2012, American Society of Hematology

    Dr Alejandro Lazo-Langner

  215. Comparing multiple competing interventions in the absence of randomized trials using clinical risk-benefit analysis

    Article • BMC Medical Research Methodology, January 2012, Springer Science + Business Media

    Dr Alejandro Lazo-Langner

  216. Bleeding risk assessment during oral anticoagulant therapy initiation

    Article • Expert Review of Hematology, January 2012, Taylor & Francis

    Dr Alejandro Lazo-Langner

  217. Study of Octaplex dosing accuracy: An in vitro analysis

    Article • Thrombosis and Haemostasis, January 2012, Thieme Publishing Group

    Dr Alejandro Lazo-Langner

  218. A Systematic Review on the Use of Intrathecal Rituximab in CNS Lymphoma

    Article • Blood, November 2011, American Society of Hematology

    Dr Alejandro Lazo-Langner

  219. Clinical Performance of Bleeding Risk Scores for Predicting Major and Clinically Relevant Non-Major Bleeding Events in Patients Receiving Oral Anticoagulant Therapy

    Article • Blood, November 2011, American Society of Hematology

    Dr Alejandro Lazo-Langner

  220. Conservative Peri-Procedural Anticoagulation Management in Patients with Venous Thromboembolic Disease Results in a Low Proportion of Thrombosis and Bleeding

    Article • Blood, November 2011, American Society of Hematology

    Dr Alejandro Lazo-Langner

  221. Study of Octaplex Dosing Accuracy: An In Vitro Analysis

    Article • Blood, November 2011, American Society of Hematology

    Dr Alejandro Lazo-Langner

  222. Clinical and Genetic Determinants of Warfarin Pharmacokinetics and Pharmacodynamics during Treatment Initiation

    Article • PLOS One, November 2011, PLOS

    Dr Alejandro Lazo-Langner

  223. Prospective evaluation of a pharmacogenetics-guided warfarin loading and maintenance dose regimen for initiation of therapy

    Article • Blood, September 2011, American Society of Hematology

    Dr Alejandro Lazo-Langner

  224. Treatment of Hodgkin lymphoma with adriamycin, bleomycin, vinblastine and dacarbazine without routine granulocyte-colony stimulating factor support does not increase the risk of febrile neutropenia: a prospective cohort study

    Article • Leukemia & Lymphoma, August 2011, Taylor & Francis

    Dr Alejandro Lazo-Langner

  225. More on: lupus anticoagulant testing during acute thrombotic events

    Article • Journal of Thrombosis and Haemostasis, August 2011, Elsevier

    Dr Alejandro Lazo-Langner

  226. The pandemic H1N1 influenza vaccine results in low rates of seroconversion for patients with hematological malignancies

    Article • Leukemia & Lymphoma, June 2011, Taylor & Francis

    Dr Alejandro Lazo-Langner

  227. Retinal-Vein Occlusion

    Article • The New England Journal of Medicine and Surgery and the Collateral Branches of Science, March 2011, New England Journal of Medicine (NEJM/MMS)

    Dr Alejandro Lazo-Langner

  228. Retinal vein thrombosis: pathogenesis and management: a rebuttal

    Article • Journal of Thrombosis and Haemostasis, February 2011, Elsevier

    Dr Alejandro Lazo-Langner

  229. Successful Intraoperative Reversal of Heparin with Factor VII in a Patient with Protamine Reaction

    Article • Innovations Technology and Techniques in Cardiothoracic and Vascular Surgery, January 2011, SAGE Publications

    Dr Alejandro Lazo-Langner

  230. Successful Intraoperative Reversal of Heparin with Factor VII in a Patient with Protamine Reaction

    Article • Innovations Technology and Techniques in Cardiothoracic and Vascular Surgery, January 2011, SAGE Publications

    Dr Alejandro Lazo-Langner

  231. The attitude of Canadian university students toward a behavior‐based blood donor health assessment questionnaire

    Article • Transfusion, December 2010, Wiley

    Dr Alejandro Lazo-Langner

  232. A Systematic Review of Diagnostic Features and Treatment Outcomes In Hemophagocytic Syndromes In the Adult Population

    Article • Blood, November 2010, American Society of Hematology

    Dr Alejandro Lazo-Langner

  233. Case Report of a Primary Splenic Marginal Zone Lymphoma Patient Presenting with Factor VII Inhibitor

    Article • Blood, November 2010, American Society of Hematology

    Dr Alejandro Lazo-Langner

  234. Development of A Clinical Prediction Rule for Risk Stratification of Recurrent Venous Thromboembolism In Patients with Cancer-Associated Venous Thromboembolism

    Article • Blood, November 2010, American Society of Hematology

    Dr Alejandro Lazo-Langner

  235. Patients with Cancer Who Develop a First Venous Thromboembolic Event After Surgery Are at High Risk of Venous Thromboembolism Recurrence During the Anticoagulation Period

    Article • Blood, November 2010, American Society of Hematology

    Dr Alejandro Lazo-Langner

  236. Predictors of Unsuccessful Mobilization with Granulocyte-Colony Stimulating Factor (G-CSF) Alone In Patients with Hematological Malignancies Undergoing Autologous Hematopoietic Stem Cell (AHSCT) Transplant

    Article • Blood, November 2010, American Society of Hematology

    Dr Alejandro Lazo-Langner

  237. The Attitude of Canadian University Students towards a Behaviour-Based Blood Donor Health Assessment Questionnaire

    Article • Blood, November 2010, American Society of Hematology

    Dr Alejandro Lazo-Langner

  238. The Pandemic H1N1 Influenza Vaccine Results In Low Rates of Seroconversion In Patients with Hematological Malignancies

    Article • Blood, November 2010, American Society of Hematology

    Dr Alejandro Lazo-Langner

  239. Validation of A Clinical Prediction Rule for Risk Stratification of Recurrent Venous Thromboembolism In Patients with Cancer-Associated Venous Thromboembolism

    Article • Blood, November 2010, American Society of Hematology

    Dr Alejandro Lazo-Langner

  240. Ambulatory management of pulmonary embolism: a pragmatic evaluation

    Article • Journal of Thrombosis and Haemostasis, November 2010, Elsevier

    Dr Alejandro Lazo-Langner

  241. Anticoagulant response after dalteparin overdose

    Article • Journal of Thrombosis and Haemostasis, October 2010, Elsevier

    Dr Alejandro Lazo-Langner

  242. Predicting warfarin dose

    Article • Current Opinion in Pulmonary Medicine, September 2010, Wolters Kluwer Health

    Dr Alejandro Lazo-Langner

  243. Ultrastructural changes and immunolocalization of P-selectin in platelets from patients with major depression

    Article • Psychiatry Research, April 2010, Elsevier

    Dr Alejandro Lazo-Langner

  244. Low molecular weight heparin for the treatment of retinal vein occlusion: a systematic review and meta-analysis of randomized trials

    Article • Haematologica, March 2010, Ferrata Storti Foundation (Haematologica)

    Dr Alejandro Lazo-Langner

  245. Cutaneous adult T-cell lymphoma leukemia

    Article • Blood, January 2010, American Society of Hematology

    Dr Alejandro Lazo-Langner

  246. Normal levels of protein C and protein S tested in the acute phase of a venous thromboembolic event are not falsely elevated

    Article • Thrombosis Journal, January 2010, Springer Science + Business Media

    Dr Alejandro Lazo-Langner

  247. A Systematic Review and Meta-Analysis of Proportions of Thrombosis and Bleeding in Patients Receiving Venous Thromboembolism (VTE) Prophylaxis After Orthopedic Surgery (OS). An Update.

    Article • Blood, November 2009, American Society of Hematology

    Dr Alejandro Lazo-Langner

  248. Inter-Observer Variability in the Assessment of the 4Ts Score for the Diagnosis of Heparin Induced Thrombocytopenia (HIT) in Patients Undergoing Cardiac Surgery (CS).

    Article • Blood, November 2009, American Society of Hematology

    Dr Alejandro Lazo-Langner

  249. Pitfalls of Clinical Diagnosis Strategies for Heparin-Induced Thrombocytopenia (HIT) After Cardiac Surgery (CS).

    Article • Blood, November 2009, American Society of Hematology

    Dr Alejandro Lazo-Langner

  250. Prevention of Venous Thromboembolism (VTE) Associated with Pregnancy in Women with a Past History of VTE.

    Article • Blood, November 2009, American Society of Hematology

    Dr Alejandro Lazo-Langner

  251. Treatment of Hodgkin Lymphoma without G-CSF Does Not Increase the Risk of Febrile Neutropenia.

    Article • Blood, November 2009, American Society of Hematology

    Dr Alejandro Lazo-Langner

  252. Predicting warfarin maintenance dose in patients with venous thromboembolism based on the response to a standardized warfarin initiation nomogram

    Article • Journal of Thrombosis and Haemostasis, August 2009, Elsevier

    Dr Alejandro Lazo-Langner

  253. A 10 mg warfarin initiation nomogram is safe and effective in outpatients starting oral anticoagulant therapy for venous thromboembolism

    Article • Thrombosis Research, July 2009, Elsevier

    Dr Alejandro Lazo-Langner

  254. Overview of Current Venous Thromboembolism Protocols in Hip Reconstruction

    Article • Orthopedic Clinics of North America, July 2009, Elsevier

    Dr Alejandro Lazo-Langner

  255. Lessons From Ximelagatran: Issues for Future Studies Evaluating New Oral Direct Thrombin Inhibitors for Venous Thromboembolism Prophylaxis in Orthopedic Surgery

    Article • Clinical and Applied Thrombosis/Hemostasis, November 2008, SAGE Publications

    Dr Alejandro Lazo-Langner

  256. Neuroinflammatory and Neurodegenerative Markers in Non-Hodgkin’s Lymphoma and Hematologic Malignancies with Central Nervous System Involvement

    Article • Blood, November 2008, American Society of Hematology

    Dr Alejandro Lazo-Langner

  257. Safe Treatment of Pulmonary Embolism on An Outpatient Basis.

    Article • Blood, November 2008, American Society of Hematology

    Dr Alejandro Lazo-Langner

  258. Intrahospital Correlation of the International Normalized Ratio

    Article • Clinical and Applied Thrombosis/Hemostasis, April 2008, SAGE Publications

    Dr Alejandro Lazo-Langner

  259. Confirmation of the Safety and Efficacy of the Kovacs 10 mg Warfarin Initiation Nomogram for Venous Thromboembolism and Derivation of a Rule To Predict the Weekly Maintenance Dose.

    Article • Blood, November 2007, American Society of Hematology

    Dr Alejandro Lazo-Langner

  260. Determining the Optimal Timing of Initiation for Venous Thromboembolism (VTE) Anticoagulant (AC) Prophylaxis (proph) after Orthopedic Surgery (OS).

    Article • Blood, November 2007, American Society of Hematology

    Dr Alejandro Lazo-Langner

  261. Long‐term dalteparin in pregnancy not associated with a decrease in bone mineral density: substudy of a randomized controlled trial

    Article • Journal of Thrombosis and Haemostasis, August 2007, Elsevier

    Dr Alejandro Lazo-Langner

  262. The effect of low‐molecular‐weight heparin on cancer survival. A systematic review and meta‐analysis of randomized trials

    Article • Journal of Thrombosis and Haemostasis, April 2007, Elsevier

    Dr Alejandro Lazo-Langner

  263. The risk of dialysis access thrombosis is related to the transforming growth factor–β1 production haplotype and is modified by polymorphisms in the plasminogen activator inhibitor–type 1 gene

    Article • Blood, December 2006, American Society of Hematology

    Dr Alejandro Lazo-Langner

  264. Clinical Outcomes in Patients Receiving Venous Thromboembolism (VTE) Prophylaxis after Orthopedic Surgery (OS). A Systematic Review and Meta-Analysis of Proportions.

    Article • Blood, November 2006, American Society of Hematology

    Dr Alejandro Lazo-Langner

  265. The Effect of Low Molecular Weight Heparin (LMWH) on Cancer Survival. A Systematic Review and Meta-Analysis (MA) of Randomized Trials.

    Article • Blood, November 2006, American Society of Hematology

    Dr Alejandro Lazo-Langner

  266. Moderate and severe neutropenia in patients with systemic lupus erythematosus

    Article • Rheumatology, February 2006, Oxford University Press (OUP)

    Dr Alejandro Lazo-Langner

  267. Prophylactic Low Molecular Weight Heparin (LMWH) during Pregnancy Is Not Associated with a Decrease in Bone Mineral Density (BMD). The TIPPS (Thrombophilia in Pregnancy Prophylaxis Study) BMD Substudy.

    Article • Blood, November 2005, American Society of Hematology

    Dr Alejandro Lazo-Langner

  268. The Risk of Dialysis Access Thrombosis Is Related to Polymorphisms in the Transforming Growth Factor-β1 and Plasminogen Activator Inhibitor-Type 1 Genes.

    Article • Blood, November 2005, American Society of Hematology

    Dr Alejandro Lazo-Langner

  269. Ximelagatran in Major Orthopedic Surgery: A Systematic Review and Meta-Analysis of Efficacy and Safety.

    Article • Blood, November 2005, American Society of Hematology

    Dr Alejandro Lazo-Langner

  270. Role of malpractice crisis in midwifery job market

    Article • Journal of Midwifery & Women s Health, June 2004, Wiley

    Dr Alejandro Lazo-Langner

  271. Contraceptive options for women with factor V leiden

    Article • Journal of Midwifery & Women s Health, May 2004, Wiley

    Dr Alejandro Lazo-Langner

  272. Methodologic pitfalls in measurement of 5-hydroxytriptamine uptake transporters in human platelets by [3H]-paroxetine binding assay

    Article • Archives of Medical Research, September 2003, Elsevier

    Dr Alejandro Lazo-Langner

  273. Platelet satellitism, spurious neutropenia, and cutaneous vasculitis: Casual or causal association?

    Article • American Journal of Hematology, June 2002, Wiley

    Dr Alejandro Lazo-Langner

  274. Effect of all‐trans‐Retinoic acid on the hypercoagulable state of patients with breast cancer

    Article • American Journal of Hematology, April 2002, Wiley

    Dr Alejandro Lazo-Langner

  275. Therapeutic plasma exchange in Mexico: Experience from a single institution

    Article • American Journal of Hematology, April 2002, Wiley

    Dr Alejandro Lazo-Langner

  276. Serum hyperviscosity syndrome responding to therapeutic plasmapheresis in a patient with primary Sjögren's syndrome

    Article • Journal of Clinical Apheresis, January 2002, Wiley

    Dr Alejandro Lazo-Langner

  277. The effects of three different LDL‐apheresis methods on the plasma concentrations of E‐selectin, VCAM‐1, and ICAM‐1

    Article • Journal of Clinical Apheresis, January 2002, Wiley

    Dr Alejandro Lazo-Langner